The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | LAURA: osimertinib and chemoradiotherapy in stage III EGFR-m NSCLC
Gerry Hanna, MBBCh, PhD, MRCP, FRCR, FRANZCR, Trinity College Dublin, Dublin, Ireland, gives an overview of safety data from the Phase III LAURA trial (NCT03521154), which evaluated osimertinib after chemoradiotherapy in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC). Osimertinib significantly improved progression-free survival and the safety profile was manageable, with radiation pneumonitis (RP) and interstitial lung disease (ILD) as the most reported adverse events. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
